NCT00591084

Ginsenoside-Rd for Acute Ischemic Stroke

Efficacy and Safety of Ginsenoside-Rd for Acute Ischemic Stroke: A Randomized, Double-blind, Placebo-controlled, Phase Ⅱ, Multicenter Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 199 (actual)
• Sponsor: Xijing Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of ginsenoside-Rd for acute ischemic stroke.

Detailed description

A major contributor to brain injury after stroke is disordered inward flow of Ca2+ and its toxic accumulation in the nervous system following cerebral ischemia. Ginsenoside-Rd, a purified component from total saponins of Panax notoginseng, has a molecular formula of C48H82O18•3H2O with a molecular weight of 1001.2. Ginsenoside-Rd has been shown to inhibit receptor-operated Ca2+ influx through receptor-and-store-operated Ca2+ channels (ROCC) , attenuate oxidative stress in stroke, reduce the size of the cerebral infarction and preserve brain functioning in animal models of acute ischemic stroke.

Conditions

• Ischemic Stroke

Interventions

Type	Name	Description
DRUG	ginsenoside-Rd 10 mg	infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days
DRUG	placebo	infusion placebo (group B)once a day and continued for 14 days
DRUG	ginsenoside-Rd 20mg	infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days

Timeline

• Start date: 2005-09-01
• Primary completion: 2006-06-01
• Completion: 2006-09-01
• First posted: 2008-01-11
• Last updated: 2010-09-01

Locations

1 site across 1 country: China